1. Includes individuals with adjusted FRS ≥10% and <20%
2. Treat individuals with LDL-C ≥3.5 mmol/L (Recommendation Strong, Quality Moderate).
3. In individuals with LDL-C <3.5 mmol/L, either apo B ≥1.2 g/L or non- HDL-C ≥4.3 mmol/L are suggested to identify patients who might benefit from pharmacotherapy (Recommendation Strong, Quality Moderate).
4. Target LDL-C ≤2.0 mmol/L or ≥50% reduction in LDL-C for intermediate-risk individuals in whom treatment is initiated (Recommendation Strong, Quality Moderate).
5. Alternate target variables: apo B ≤0.8 g/L or non-HDL-C ≤2.6 mmol/L (Recommendation Strong, Quality Moderate).

Values and Preferences

• Non-HDL-C is available without additional cost or testing and there are increasing data to demonstrate its potential value
• Non-HDL-C is particularly useful where apo B is not available and in patients whose triglyceride level is >1.5 mmol/L
• Non-HDL-C, like apo B, also has the advantage of being applicable in a nonfasting state